Antiviral activity of TMC435, an oral, once-daily, HCV NS3/4A protease inhibitor, was evaluated with pegylated interferon-α2a/ribavirin (P/R) in HCV genotype-1 patients.
Methods
Optimal Protease inhibitor Enhancement of Response to TherApy (OPERA-1; TMC435-C201; NCT00561353) is a Phase IIa, randomized, placebo-controlled study. Treatment-naive patients (n=74) received 25, 75 or 200 mg TMC435 once daily, or placebo for 7 days followed by 21 days of triple therapy with P/R, or triple therapy for 28 days. Treatment-experienced patients (n=37; 56.8% with cirrhosis) received 75, 150 or 200 mg TMC435 once daily, or placebo with P/R for 28 days. Patients continued P/R up to week 48.
Results
Treatment-naive patients who received initial monotherapy had a rapid decline in HCV RNA by day 3. At day 7, HCV RNA reductions were greatest for the 75 and 200 mg doses (0.02, -2.63, -3.43 and -4.13 log10 IU/ml for placebo, and TMC435 25, 75 and 200 mg, respectively). At day 28, all patients who received triple therapy with TMC435 75 or 200 mg had HCV RNA<25 IU/ml versus 4/9 for placebo. In total, 18/28 treatment- experienced patients (9/9 prior relapsers, 9/19 non-responders) who received TMC435 had HCV RNA<25 IU/ml at day 28 versus 0/9 for placebo; similar results were observed for the 150 and 200 mg doses. Most adverse events were grade 1/2. No relevant changes in laboratory parameters occurred, except mild and reversible bilirubin elevations, mostly at the 200 mg dose.
Conclusions
Once-daily TMC435 with P/R showed potent, dose-dependent antiviral activity over 28 days, and had a favourable tolerability profile.
References
1.
MannsM.P., FosterG.R., RockstrohJ.K., ZeuzemS., ZoulimF., HoughtonM.The way forward in HCV treatment – finding the right path. Nat Rev Drug Discov2007; 6: 991–1000.
2.
ChooQ.L., KuoG., WeinerA.J., OverbyL.R., BradleyD.W., HoughtonM.Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science1989; 244: 359–362.
3.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958–965.
4.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975–982.
5.
StraderD.B., WrightT., ThomasD.L., SeeffL.B. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology2004; 39: 1147–1171.
6.
AsselahT., BenhamouY., MarcellinP.Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int2009; 29Suppl 1: 57–67.
7.
CholongitasE., PapatheodoridisG.V.Review article: novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther2008; 27: 866–884.
8.
LinK., PerniR.B., KwongA.D., LinC.VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother2006; 50: 1813–1822.
9.
HézodeC., ForestierN., DusheikoG.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med2009; 360: 1839–1850.
10.
PoordadF., McConeJ.Jr., BaconB.R.Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med2011; 364: 1195–1206.
11.
BaconB.R., GordonS.C., LawitzE.Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med2011; 364: 1207–1217.
12.
JacobsonI.M., McHutchisonJ.G., DusheikoG.Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med2011; 364: 2405–2416.
13.
ZeuzemS., AndreoneP., PolS.Telaprevir for retreatment of HCV infection. N Engl J Med2011; 364: 2417–2428.
14.
McHutchisonJ.G., MannsM.P., MuirA.J.Telaprevir for previously treated chronic HCV infection. N Engl J Med2010; 362: 1292–1303.
15.
LinT.I., LenzO., FanningG.In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother2009; 53: 1377–1385.
16.
ReesinkH.W., FanningG.C., FarhaK.A.Rapid HCV-RNA decline with once daily TMC435: a Phase I study in healthy volunteers and hepatitis C patients. Gastroenterology2010; 138: 913–921.
17.
ReesinkH., de BruijneC., WeeginkC.Antiviral activity and safety of TMC435 combined with pegylated interferon and ribavirin in hepatitis C patients with genotype-1 who had previous exposure to TMC435.60th Annual Meeting of the American Association for the Study of Liver Diseases, 30 October–3 November 2009, Boston, MA, USA. Poster 1563.
DumontS., FeveryB., Van den BrandeK.Development of a platform to detect drug resistance mutations in the non-structural protein region of the hepatitis C virus genotypes 1, 2, 3 and 4. J Hepatol2009; 50Suppl 1: S124.
21.
LenzO., VerbinnenT., LinT.I.In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother2010; 54: 1878–1887.
22.
LenzO., VejgenL., LinT., PeetersM., De SmedtG., PicchioG.Virologic analysis of genotype-1-infected patients treated with once-daily TMC435 during the Optimal Protease inhibitor Enhancement of Response to TherApy (OPERA)-1 study.61st AASLD Meeting. 29 October – 2 November 2010, Boston, MA, USA. Poster 812.
23.
LenzO., VerbinnenT., LinT-I. In vitro resistance profile of the HCV NS3/4A inhibitor TMC435350.15th International Symposium on Hepatitis C Virus and Related Viruses. 5–9 October 2008, San Antonio, TX, USA. Poster 294.
